4-(2-oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylic acid ethyl ester | 906532-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-(2-oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylic acid ethyl ester
• 英文别名: 4-(2-oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidine-1-ethyl carboxylate；ethyl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate；Ctv4Q3F76P；ethyl 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
• CAS: 906532-82-9
• 化学式: C₁₄H₁₈N₄O₃
• 分子量: 290.322
• InChiKey: VPVGUOWDUKXHQC-UHFFFAOYSA-N

物化性质

• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylic acid ethyl ester 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 生成 N-[(3R,6S)-6-(2,3-二氟苯基)六氢-2-氧代-1-(2,2,2-三氟乙基)-1H-氮杂卓-3-基]-4-(2,3-二氢-2-氧代-1H-咪唑并[4,5-b]吡啶-1-基)-1-哌啶甲酰胺
  参考文献：
  名称：

  WO2007/120590

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(2-氯吡啶-3-基氨基)哌啶-1-甲酸乙酯 在 palladium diacetate 、 potassium carbonate 、 1,4-双(二苯基膦)丁烷 作用下， 以 四氢呋喃 、 醋酸异丙酯 、 异丙醇 为溶剂， 反应 22.0h， 生成 4-(2-oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

  摘要：

  这项发明涉及一般式(I)的新型杂环化合物，以及它们的药用盐和对映体。该发明还涉及将其用作药物产品，优选用于预防和/或治疗具有神经源性成分的炎症性疾病，或将其用作化妆品。本发明的化合物作为CGRP-R受体的拮抗剂。

  公开号：

  US20180050992A1

文献信息

• Process for the preparation of Caprolactam Cgrp Antagonist
  申请人：Palucki Michael

  公开号：US20090124799A1

  公开（公告）日：2009-05-14

  An efficient syntheses for the preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one.

  一种高效合成方法，用于制备(3R,6S)-3-氨基-6-(2,3-二氟苯基)-1-(2,2,2-三氟乙基)氮杂七环-2-酮。
• Process for the Preparation of Cgrp Antagonist
  申请人：Belyk Kevin

  公开号：US20090281306A1

  公开（公告）日：2009-11-12

  An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1′-carbonyldiimidazole (“CDI”) as carbonyl source; and an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide.

  一种高效的合成方法，用于制备N-[(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂丙酰胺基]-4-(2-氧代-2,3-二氢-1H-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酰胺，通过将(3R,6S)-3-氨基-6-(2,3-二氟苯基)-1-(2,2,2-三氟乙基)氮杂丙酮和2-氧代-1-(4-哌啶基)-2,3-二氢-1H-咪唑并[4,5-b]吡啶二盐酸盐与1,1'-羰基二咪唑（“CDI”）作为羰基源进行偶联；以及一种高效的制备钾盐的方法N-[(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂丙酰胺基]-4-(2-氧代-2,3-二氢-1H-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酰胺。
• CGRP Antagonist Salt
  申请人：Belyk Kevin

  公开号：US20100286122A1

  公开（公告）日：2010-11-11

  An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1 -yl)piperidine-1-carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1′-carbonyldiimidazole (“CDI”) as carbonyl source; an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1 -yl)piperidine-1-carboxamide; efficient syntheses for the preparation of intermediates (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride, and the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide including the potassium salt ethanolate and potassium salt hydrate.

  一种高效合成方法，用于制备N-[(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂七环-3-基]-4-(2-氧代-2,3-二氢-1H-咪唑[4,5-b]吡啶-1-基)哌啶-1-羧酰胺，通过将(3R,6S)-3-氨基-6-(2,3-二氟苯基)-1-(2,2,2-三氟乙基)氮杂七环-2-酮和2-氧代-1-(4-哌啶基)-2,3-二氢-1H-咪唑[4,5-b]吡啶二盐酸盐与1,1'-羰基二咪唑（“CDI”）做为羰基源进行偶联；一种高效制备钾盐的方法，用于制备N-[(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂七环-3-基]-4-(2-氧代-2,3-二氢-1H-咪唑[4,5-b]吡啶-1-基)哌啶-1-羧酰胺；高效合成方法，用于制备中间体(3R,6S)-3-氨基-6-(2,3-二氟苯基)-1-(2,2,2-三氟乙基)氮杂七环-2-酮和2-氧代-1-(4-哌啶基)-2,3-二氢-1H-咪唑[4,5-b]吡啶二盐酸盐，以及N-[(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂七环-3-基]-4-(2-氧代-2,3-二氢-1H-咪唑[4,5-b]吡啶-1-基)哌啶-1-羧酰胺的钾盐乙醇酸盐和钾盐水合物的高效制备方法。
• Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate
  申请人：McLaughlin Mark

  公开号：US20090176986A1

  公开（公告）日：2009-07-09

  An efficient syntheses for the preparation of the intermediate 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride, and other salt forms of 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine.

  一种高效的合成方法，用于制备中间体2-氧代-1-(4-哌啶基)-2,3-二氢-1H-咪唑[4,5-b]吡啶二盐酸盐，以及其他盐酸盐形式的2-氧代-1-(4-哌啶基)-2,3-二氢-1H-咪唑[4,5-b]吡啶。
• Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine
  作者：Christopher S. Burgey、Craig A. Stump、Diem N. Nguyen、James Z. Deng、Amy G. Quigley、Beth R. Norton、Ian M. Bell、Scott D. Mosser、Christopher A. Salvatore、Ruth Z. Rutledge、Stefanie A. Kane、Kenneth S. Koblan、Joseph P. Vacca、Samuel L. Graham、Theresa M. Williams

  DOI：10.1016/j.bmcl.2006.07.044

  日期：2006.10

  In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented. (c) 2006 Elsevier Ltd. All rights reserved.